• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Domain grants Prexton exclusive license and development of mGluR4 PAMs for Parkinson’s

Domain grants Prexton exclusive license and development of mGluR4 PAMs for Parkinson’s

January 25, 2013
CenterWatch Staff

Domain Therapeutics, a French biopharmaceutical company, has granted Switzerland–based Prexton Therapeutics an exclusive option to license and develop metabotropic glutamate receptor 4 (mGluR4) Positive Allosteric Modulator (PAM) drugs targeting Parkinson’s disease.

The chemical series was previously developed through a licensing and collaboration agreement signed between Domain and Merck Serono, a division of Merck, in January 2011. This agreement between Domain Therapeutics and Prexton Therapeutics—a spin-off company of Merck Serono formed around its R&D portfolio in the field of Parkinson’s disease—follows a strategic decision from Merck Serono to focus its research efforts on certain diseases such as multiple sclerosis, cancer and immune-mediated diseases.

“We are pleased to sign this agreement with former seasoned scientists of Merck Serono, who had been involved in this mGluR4 PAM project within Merck Serono,” said Pascal Neuville, CEO of Domain Therapeutics. “We are very confident that this newly founded company with a unique focus on mGluRs for neurodegenerative diseases will be the best partner to drive the project to an Investigational New Drug (IND) stage and then ensure its clinical development.”

Francois Conquet, CEO of Prexton Therapeutics, said, “I had the opportunity to follow Domain’s mGluR4 PAM compounds and I am very glad that we can benefit from the collaborative work led by Domain and Merck Serono. This license option agreement clearly strengthens Prexton’s franchise in the business of mGluR drugs.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing